Recent studies have identified promising therapeutic strategies addressing liver and kidney pathologies. In liver cancer associated with metabolic dysfunction–associated steatohepatitis (MASH-HCC), selective inhibition of ATP citrate lyase (ACLY) was shown to reprogram the tumor microenvironment, invoking a potent immune response predominantly driven by B cells and suppressing tumor progression. Concurrently, advancements in kidney transplantation techniques, including normothermic machine perfusion (NMP), are enabling improved organ preservation and assessment for enhanced graft outcomes. Such innovations are driving precision medicine approaches in hepatology and nephrology.